Emergent BioSolutions | EBS - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Akebia Therapeutics USD -11.24M 12.39M 2025-12
ALKERMES USD -61.93M 122.3M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amarin USD -852K 7.26M 2025-12
ANI Pharmaceuticals USD 40.22M 8.74M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Coherus Biosciences USD -46.35M 90.86M 2025-12
Exelixis USD 262.68M 5.01M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -114M 21M 2026-06
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
Lonza CHF 624M 197M 2024-12
Merck USD -3.53B 6.95B 2026-03
Moderna USD -1.33B 535M 2026-03
Myriad Genetics USD 4.6M 3.4M 2025-12
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Pacira USD 5M 4.43M 2026-03
Pfizer USD -653M 5.84B 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Sanofi EUR 837M 1.17B 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
United Therapeutics USD 372.7M 54.4M 2026-06
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12